Febuxostat and Increased Dialysis as a Treatment for Severe Tophaceous Gout in a Hemodialysis Patient.

Case Rep Nephrol

Division of Nephrology, University of California, San Francisco, San Francisco, CA 94143, USA.

Published: May 2016

Uric acid accumulates in renal failure and is thought to be a uremic toxin-that is, higher levels of uric acid are more damaging to the kidneys. Urate crystals can precipitate in the kidney tubules, cause urate stones, and promote inflammatory changes in the renal interstitium and vascular endothelium. Uric acid is also a small non-protein-bound molecule and therefore easily dialyzable. Here, we present the case of an anuric hemodialysis patient with severe tophaceous gout who regained some renal function and whose gout burden significantly decreased resulting in marked improvement in functional status using a new gout medication, febuxostat, and increased frequency of dialysis.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4856909PMC
http://dx.doi.org/10.1155/2016/9106935DOI Listing

Publication Analysis

Top Keywords

uric acid
12
febuxostat increased
8
severe tophaceous
8
tophaceous gout
8
hemodialysis patient
8
increased dialysis
4
dialysis treatment
4
treatment severe
4
gout
4
gout hemodialysis
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!